Market Place
Sourcing Support
Immunome Reports Q3 2024 Financial Results & Business Update
13 Nov 2024 //
BUSINESSWIRE
Immunome to Present at Guggenheim’s Inaugural Health Conference
05 Nov 2024 //
BUSINESSWIRE
Immunome Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
01 Nov 2024 //
BUSINESSWIRE
Immunome Presents Compelling Data for IM-1021 Anti-Tumor Activity
29 Oct 2024 //
BUSINESSWIRE
Immunome To Present Preclinical Data On IM-1021 At EORTC Symposium
18 Oct 2024 //
BUSINESSWIRE
Immunome Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
08 Oct 2024 //
BUSINESSWIRE
Immunome Appoints Roee Shahar As Executive Vice President
08 Oct 2024 //
BUSINESSWIRE
Immunome To Present Updated AL102 RINGSIDE Trial Results At ESMO 2024
13 Sep 2024 //
BUSINESSWIRE
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
29 Aug 2024 //
BUSINESSWIRE
Immunome Reports Q2 2024 Results And Provides Business Update
12 Aug 2024 //
BUSINESSWIRE
Immunome Appoints Phil Tsai as Chief Technical Officer
27 Jun 2024 //
BUSINESSWIRE
Immunome Reports Q1 2024 Results, Business Update
14 May 2024 //
BUSINESSWIRE
Immunome to Present at 2024 Bank of America Healthcare Conference
08 May 2024 //
BUSINESSWIRE
Immunome Appoints Kinney Horn as Chief Business Officer
02 May 2024 //
BUSINESSWIRE
Immunome Appoints Sandra M. Swain to Board of Directors
25 Apr 2024 //
BUSINESSWIRE
Immunome to Present Data for IM-3050 at 2024 AACR Annual Meeting
05 Apr 2024 //
BUSINESSWIRE
Immunome Reports Full Year 2023 Financial Results
28 Mar 2024 //
BUSINESSWIRE
Immunome Completes Acquisition of AL102 From Ayala
26 Mar 2024 //
BUSINESSWIRE
ArrayPlex Platform Selected for Use in Discovery of Targeted Cancer Therapies
18 Mar 2024 //
BUSINESSWIRE
Immunome to Participate in the Leerink Partners Global Biopharma Conference
07 Mar 2024 //
BUSINESSWIRE
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
01 Mar 2024 //
BUSINESSWIRE
Ayala’s Announced Completion of Enrollment in Phase 3 Evaluating AL102
20 Feb 2024 //
BUSINESSWIRE
Immunome Announces Closing of Public Offering
16 Feb 2024 //
BUSINESSWIRE
Immunome Announces Proposed Public Offering of Common Stock
13 Feb 2024 //
BUSINESSWIRE
Immunome Announces Pricing of Public Offering of Common Stock
13 Feb 2024 //
BUSINESSWIRE
Immunome pays $50M for Ayala`s phase 3 desmoid tumor drug
06 Feb 2024 //
FIERCE BIOTECH
Immunome to Present at the 6th Annual Biotechnology Conference
05 Feb 2024 //
BUSINESSWIRE
Immunome Licenses Zentalis ROR1 Antibody-Drug Conjugate
08 Jan 2024 //
BUSINESSWIRE
Immunome Appoints Phil Roberts as Chief Technical Officer
04 Jan 2024 //
BUSINESSWIRE
Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
BUSINESSWIRE
Immunome Appoints Carol A. Schafer to Board of Directors
02 Jan 2024 //
BUSINESSWIRE
Immunome to Acquire Antibody-Related Assets and Materials from Atreca
26 Dec 2023 //
BUSINESSWIRE
Immunome to Present at the Stifel 2023 Healthcare Conference
10 Nov 2023 //
BUSINESSWIRE
Immunome Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
BUSINESSWIRE
Immunome Appoints Jean-Jacques Bienaimé to Board of Directors
08 Nov 2023 //
BUSINESSWIRE
Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer
19 Oct 2023 //
BUSINESSWIRE
Immunome and Morphimmune Announce Successful Completion of Merger
03 Oct 2023 //
BUSINESSWIRE
Immunome Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
BUSINESSWIRE
Immunome & Morphimmune Announce Definitive Merger Agreement of $125 Million
29 Jun 2023 //
BUSINESSWIRE
Immunome Publishes Research Demonstrating that Inhibition of IL-38
23 May 2023 //
BUSINESSWIRE
Immunome Reports First Quarter 2023 Financial Results
05 May 2023 //
BUSINESSWIRE
Immunome Reports Fourth Quarter and Full Year 2022 Financial Results
16 Mar 2023 //
BUSINESSWIRE
Immunome stops Covid-19 work; Hookipa drops CMV vaccine
16 Mar 2023 //
ENDPTS
Immunome decides not to top up its COVID antibody cocktail
16 Mar 2023 //
FIERCE BIOTECH
Immunome to Present at 13th Annual World ADC London Conference
09 Mar 2023 //
BUSINESSWIRE
Immunome Announces Formation of Antibody-Drug Conjugate Advisory Board
08 Feb 2023 //
BUSINESSWIRE
AbbVie & Immunome Announce Collaboration to Discover Multiple Novel Onco Targets
06 Jan 2023 //
PR NEWSWIRE
Immunome Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
BUSINESSWIRE
Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059
07 Nov 2022 //
BUSINESSWIRE
Immunome Announces Publication Highlighting B Cell Repertoires in Patients
23 Aug 2022 //
BUSINESSWIRE
Immunome Reports Second Quarter 2022 Financial Results
05 Aug 2022 //
BUSINESSWIRE
Immunome’s COVID-19 Cocktail Retains Neutralizing Activity Against Subvariants
06 Jul 2022 //
BUSINESSWIRE
Immunome Initiates Phase 1b Study of IMM-BCP-01 for COVID-19
09 Jun 2022 //
BUSINESSWIRE
Immunome to Present at the Jefferies Healthcare Conference
02 Jun 2022 //
BUSINESSWIRE
Immunome Provides R&D Update on Lead Oncology Candidate Targeting IL-38
23 May 2022 //
BUSINESSWIRE
Immunome Shows Data on COVID-19 Ab Cocktail Potently Clears Omicron Variants
19 May 2022 //
BUSINESSWIRE
Immunome Reports First Quarter 2022 Financial Results
12 May 2022 //
BUSINESSWIRE
Immunome Reports Fourth Quarter and Full Year 2021 Financial Results
28 Mar 2022 //
BUSINESSWIRE
Immunome: FDA Lifts Clinical Hold On IMM-BCP-01 IND Application
12 Mar 2022 //
NASDAQ
Immunome’s Ab Cocktail Effective Against Omicron Variant in In Vitro Testing
08 Feb 2022 //
BUSINESSWIRE
